TNF and uveitis: For AS-associated AU, the efficacy of TNFi for reducing intraocular inflammation or prevention of uveitis recurrence has been evaluated, and previous studies observed that the majority of uveitis occurrences tend to manifest within the short-term period, specifically the first 2 years following the initiation of TNF inhibitor therapy [7,8].